Translate Bio Inc (TBIO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

29 HARTWELL AVENUE LEXINGTON, MA 02421

Translate Bio, Inc. operates as a therapeutics company. The Company develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio serves patients in the State of Massachusetts.

Data as of 2020-11-22
Market Cap1.362 Billion Shares Outstanding74.322 Million Avg 30-day Volume917.354 Thousand
P/E Ratio-16.7 Dividend Yield EPS-1.1
Price/Sales14.912 Price cash flow ratio4.9 Price free cash flow ratio5.9
Book Value4.92 Price to Tangible Book5.18 Alpha0.03
Short Interest Ratio % Short Interest to Float R-squared0.005071
BETA0.329225 52-week High/Low28.09 / 6.8 Stddev0.261801

Are you looking for this stock instead?

View SEC Filings from TBIO instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 5 -60.0% 0 (0.0%) 1 (0.06%) -100.0%
Funds Holding: 131 132 -0.76% 42 (2.76%) 48 (3.11%) -12.5%
13F shares: 69.03 Million 66.087 Million 4.45% 29.365 Million 31.258 Million -6.06%
% Ownership 92.9776 89.0138 4.45% 39.5519 42.1017 -6.06%
New Positions: 28 67 -58.21% 11 35 -68.57%
Increased Positions 59 45 31.11% 18 7 157.14%
Closed Positions 28 9 211.11% 17 4 325.0%
Reduced Positions 27 11 145.45% 9 4 125.0%
Total Calls 135.616 Thousand 358.237 Thousand -62.14% 14.1 Thousand 299.2 Thousand -95.29%
Total Puts 349.211 Thousand 275.613 Thousand 26.7% 45.7 Thousand 83.3 Thousand -45.14%
PUT/CALL Ratio 2.57 0.77 233.77% 3.24 0.28 1057.14%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding TBIO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TBIO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

53 Thousand total shares from 2 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

RENAUD RONALD C JR CHIEF EXECUTIVE OFFICER, PRES.

  • Officer
  • Director
939,388 2020-11-16 2

FORMELA JEAN FRANCOIS

  • Director
3,833,122 2020-08-25 2

SHIRE HUMAN GENETIC THERAPIES, INC.

TAKEDA PHARMACEUTICAL CO LTD

  • 10% Owner
0 2020-06-30 2

BAUPOST GROUP LLC/MA

BAUPOST GROUP GP, L.L.C.

KLARMAN SETH A

  • 10% Owner
18,044,239 2020-06-26 1

PLENGE ROBERT M

  • Director
0 2020-06-16 1

BECKMAN DANIELLA

  • Director
0 2020-06-16 1

MEYER ROBERT J.

  • Director
0 2020-06-16 1

HUGHES OWEN

  • Director
0 2020-06-16 1

LYNCH DANIEL

  • Director
0 2020-06-16 1

DEMETRI GEORGE

  • Director
0 2020-06-16 1

WOOSTER RICHARD CHIEF SCIENTIFIC OFFICER

  • Officer
0 2020-03-03 1

BARBIER ANN CHIEF MEDICAL OFFICER

  • Officer
0 2020-03-03 1

BURGESS PAUL D. CHIEF OPERATING OFFICER, CLO

  • Officer
  • SECRETARY
0 2020-03-03 1

SCHROER JOHN R. CHIEF FINANCIAL OFFICER

  • Officer
  • TREASURER
0 2020-03-03 1

TAKEDA PHARMACEUTICAL CO LTD

  • 10% Owner
7,078,945 2019-01-08 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

RENAUD RONALD C JR - Director - Officer CHIEF EXECUTIVE OFFICER, PRES.

2020-11-18 19:30:43 -0500 2020-11-16 M 53,004 $7.39 a 488,563 direct 1.6084 7.3211 7.3211 6 0.0 1

RENAUD RONALD C JR - Director - Officer CHIEF EXECUTIVE OFFICER, PRES.

2020-11-18 19:30:43 -0500 2020-11-16 M 53,004 d 1,085,673 direct

RENAUD RONALD C JR - Director - Officer CHIEF EXECUTIVE OFFICER, PRES.

2020-11-18 19:30:43 -0500 2020-11-16 M 3 $8.34 a 488,566 direct 1.6084 7.3211 7.3211 6 0.0 1

RENAUD RONALD C JR - Director - Officer CHIEF EXECUTIVE OFFICER, PRES.

2020-11-18 19:30:43 -0500 2020-11-16 M 3 d 89,997 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments